A Randomized, Single-Blind, Fixed-Order Crossover Study to Assess the Effects of CSX-1004 Injection on Fentanyl-Induced Respiratory Depression in Healthy Adult Subjects and Subjects with Opioid Use Disorder
Latest Information Update: 11 Aug 2026
At a glance
- Drugs CSX 1004 (Primary)
- Indications Opioid-related disorders
- Focus Proof of concept; Therapeutic Use
- Sponsors Cessation Therapeutics
Most Recent Events
- 20 Jun 2024 New trial record